Sydney Addiction Seminars - Depot Buprenorphine: Will it be a Game Changer?

4 September 2019

Perhaps the greatest disincentive to opioid pharmacotherapy for opioid dependence is the need for supervised dosing, which is inconvenient, time-consuming, expensive and often poorly compatible with life activities that hallmark “recovery”. With the introduction of subcutaneous depot buprenorphine injections, this level of monitoring and attendance may no longer be required.

Upcoming depot buprenorphine preparations will allow for weekly or monthly dosing, which have the potential to revolutionise how opioid agonist treatment is delivered, provide increased access for patients, and have major implications for treatment/service delivery. 

How and when will these treatments be rolled out in Australia? Are there any down sides to this new treatment modality? Will it change people’s preference for treatment medication? How will dose tapering towards eventual “graduation” be accomplished? These and other questions will be dealt with in this seminar.

Course Objectives

At the end of this seminar, you will be able to: 

  1. Show understanding of the clinical pharmacology of the different depot buprenorphine products and formulations, and how that translates into treatment guidelines.
  2. Show familiarity with the safety and side effect profiles of these medications, including precautions and contraindications.
  3. Show knowledge of induction and dosing schedules for depot buprenorphine.
  4. Demonstrate an informed approach to treatment matching among opioid pharmacotherapies including depot buprenorphine.

Event details



Sydney Addiction Seminars - Depot Buprenorphine: Will it be a Game Changer?

Where Please refer to the registration page for details. When

4 September 2019


Outlook / iCal Yahoo! Windows Live! Google